Compare KELYB & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYB | KROS |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | 5570 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.9M | 584.9M |
| IPO Year | N/A | 2020 |
| Metric | KELYB | KROS |
|---|---|---|
| Price | $15.18 | $11.33 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $22.25 |
| AVG Volume (30 Days) | 86.9K | ★ 301.4K |
| Earning Date | 01-01-0001 | 06-05-2026 |
| Dividend Yield | ★ 1.98% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | N/A | ★ 2.30 |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | $0.72 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $5.09 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.38 | $9.12 |
| 52 Week High | $125.00 | $22.55 |
| Indicator | KELYB | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 15.63 |
| Support Level | $11.79 | N/A |
| Resistance Level | $18.66 | $15.21 |
| Average True Range (ATR) | 1.39 | 0.69 |
| MACD | -0.22 | -0.38 |
| Stochastic Oscillator | 54.21 | 8.53 |
Kelly Services Inc is a provider of workforce solutions and consulting, and staffing services to a diverse group of clients operating in the Americas, Europe, and the Asia-Pacific region across various industries. The company's reportable segments are: Enterprise Talent Management, Science, Engineering and Technology, and Education. Maximum revenue is generated from its Enterprise Talent Management segment, which delivers temporary staffing, outcome-based, and permanent placement services focused on light industrial, contact center, and office and clerical specialties in North America across various industries. It also provides talent supply chain and workforce talent solutions, including MSP, RPO, and PPO solutions to its clients. Geographically, it derives key revenue from the USA.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.